Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.67 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | KCNK3 | O14649 | 15/20 | 0.56 |
| ▸ | KCNK9 | Q9NPC2 | 15/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31448497 | 0.99 | KDM4E (0.66) | KDM4ESLC2A1GAAKCNK3KCNK9 | |
| SCHEMBL22916193 | 0.90 | KDM4E (0.67) | KDM4ESLC2A1GAAKCNK3KCNK9 | |
| Hydrochloric Acid SCHEMBL31448454 | 0.90 | KDM4E (0.67) | KDM4ESLC2A1GAAKCNK3KCNK9 | |
| Hydrochloric Acid SCHEMBL31448417 | 0.89 | KDM4E (0.65) | KDM4ESLC2A1GAAKCNK3KCNK9 | |
| SCHEMBL22916196 | 0.86 | KDM4E (0.68) | KDM4ESLC2A1GAAKCNK3KCNK9 | |
| SCHEMBL22916251 | 0.86 | KDM4E (0.49) | KDM4ESLC2A1GAAKCNK3KCNK9 | |
| Hydrochloric Acid SCHEMBL31448517 | 0.85 | KDM4E (0.48) | KDM4ESLC2A1GAAKCNK3KCNK9 | |
| SCHEMBL24208174 | 0.84 | KCNK3 (0.65) | KCNK3KCNK9 | |
| Hydrochloric Acid SCHEMBL20589845 | 0.84 | KCNK3 (0.64) | KCNK3KCNK9 | |
| SCHEMBL22636358 | 0.82 | KCNK3 (0.68) | KDM4ESLC2A1GAAKCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023118126-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | WO | disclosed |
| US-20210024545-A1 | SUBSTITUTED DIAZAHETERO-BICYCLIC COMPOUNDS AND THEIR USE | BAYER AKTIENGESELLSCHAFT (DE) | 2021-01-28 | — | — | US | disclosed |
| WO-2018015196-A1 | SUBSTITUTED DIAZAHETERO-BICYCLIC COMPOUNDS AND THEIR USE | BAYER AKTIENGESELLSCHAFT (DE) | 2018-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024545-A1 | SUBSTITUTED DIAZAHETERO-BICYCLIC COMPOUNDS AND THEIR USE | HYOU1, DDAH1, VDAC3 | KDM4E 1973/4885SLC2A1 3098/4885GAA 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.